China National Medicines (SHSE:600511) Growth Rank: 9 (As of Sep. 20, 2026) — 10% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600511 China National Medicines Corp Ltd SHSE:600511
87 GF Score
Price ¥26.06
GF Value ¥32.21
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China National Medicines Growth Rank?

China National Medicines SHSE:600511 +0.08% 87 Growth Rank is 9 as of Sep. 20, 2026, which is 10% below its 10-year median of 10.00. GuruFocus rates SHSE:600511 with a GF Score™ of 87/100 and a GF Value™ of ¥32.21 (Modestly Undervalued). The stock has 3 warning signs investors should review.

China National Medicines has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

China National Medicines Growth Rank Related Terms

SHSE:600511 vs MCK, COR, CAH: Growth Rank Comparison

For the Medical Distribution subindustry, China National Medicines's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China National Medicines Growth Rank vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Medicines's Growth Rank distribution charts can be found below:

* The bar in red indicates where China National Medicines's Growth Rank falls into.


SHSE:600511
87GF Score
China National Medicines Corp Ltd SHSE:600511
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
China National Medicines (SHSE:600511) has a Growth Rank of 9 as of Sep. 20, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on China National Medicines and its competitors. This is 10% below median its historical median of 10.00. Over the past decade, China National Medicines' Growth Rank has ranged from 7.00 to 10.00.
Is China National Medicines' Growth Rank too high?
China National Medicines' current Growth Rank of 9 is 10% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 10.00. Overall, China National Medicines has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Growth Rank compare to MCK and COR?
China National Medicines' Growth Rank of 9 can be compared against companies in the Medical Distribution industry. Historically, China National Medicines' own Growth Rank has ranged from 7.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Distribution company?
A good Growth Rank depends on the Medical Distribution industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on China National Medicines and its competitors. China National Medicines's current Growth Rank is 9, which is 10% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.21, compared to a current price of ¥26.06 — trading 19.1% below its estimated fair value. The current Growth Rank is 9, which is 10% below median its 10-year median of 10.00. China National Medicines' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Growth Rank is 9 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China National Medicines (SHSE:600511) Overvalued in 2026?

Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued. The current stock price of ¥26.06 is trading 19.1% below its estimated GF Value™ of ¥32.21. GuruFocus considers China National Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:600511:

  • Growth Rank: 9 (10% below median its 10-year median of 10.00)
  • GF Value™: ¥32.21 vs. price of ¥26.06 (19.1% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China National Medicines Business Description

Address No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
87GF Score

Get the complete analysis for SHSE:600511

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.06
Price
¥32.21
GF Value